Furthermore, over thirty scientists received specialised training on numerous aspects of vaccine development, being provided with a thorough overview of the full vaccine development process, and more than twenty innovative scientific papers were published from TRANSVAC's research and activities (for more information see also tables below and: Geels, M. et al (2015): TRANSVAC research infrastructure — Results and lessons learned from the European
network of vaccine research and development.
Geels M, Thøgersen RL, Guzman CA, Ho MM, Verreck F, Collin N, Robertson JS, McConkey SJ, Kaufmann SH, Leroy O. TRANSVAC research infrastructure - Results and lessons learned from the European
network of vaccine research and development.
Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB) European Research Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European
network of vaccine research and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
TRANSVAC2 builds upon the success of TRANSVAC, the European
Network of Vaccine Research and Development funded under the EC's previous Framework Programme (FP7).
Not exact matches
Dr. Larry Corey, Principal Investigator, HIV
Vaccine Trials
Network; Past President and Director, Fred Hutchinson Cancer
Research Center Dr. Diane Havlir, Professor
of Medicine, University
of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine
The
research and public - health
networks established during the SARS epidemic — and the body
of coronavirus
research that followed — puts scientists today in a much stronger position to understand the latest virus and to develop countermeasures such as drugs and
vaccines, should they be required.
Dr. Rabinovich has served in Chief
of the Clinical and Regulatory Affairs Branch at the US National Institute
of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation
of vaccines through a
network of US clinical
research units.
Tags: aspirin, Bezos, bioengineering, Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical
Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral
Research, Colorectal Cancer, genome, hiv, hiv
vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral
vaccine, hiv
vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral
vaccine trials
network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis
of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational
research, Vaccine and Infectious Disease, Vaccine development - Viral
research,
Vaccine and Infectious Disease, Vaccine development - Viral
Vaccine and Infectious Disease,
Vaccine development - Viral
Vaccine development - Viral cancers
«We are in the midst
of an unprecedented time in HIV
vaccine research,» said Dr. Larry Corey, who leads the HIV Vaccine Trials N
vaccine research,» said Dr. Larry Corey, who leads the HIV
Vaccine Trials N
Vaccine Trials
Network.
Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV
Vaccine Trials
Network at the Fred Hutchinson Cancer
Research Center where she led multi-disciplinary teams in the design and implementation
of clinical trials evaluating candidate HIV and tuberculosis
vaccines.
In one eye - opening review
of recent
research, Charles Drake, M.D., Ph.D.,
of Johns Hopkins, who is also a member
of CRI's clinical trials
network, discussed several cancer
vaccines that are making progress, including coxsackievirus A21, an oncolytic virus
vaccine being studied in late stage melanoma, and NewLink's algenpantucel - L in pancreatic cancer (HyperAcute ® pancreas).
Sanjay Gurunathan from Sanofi Pasteur, manufacturer
of one
of the
vaccines used in RV144, said a new partnership
of the US National Institute
of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV
Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 p
Vaccine Trials
Network, US Military HIV
Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase
vaccine efficacy from the 31.2 percent of the RV144 trial to 50 p
vaccine efficacy from the 31.2 percent
of the RV144 trial to 50 percent.
National Institute
of Allergy and Infectious Diseases (NIAID) NIAID is the primary agency
of the US government devoted to
research on HIV / AIDS and the sponsor
of the HIV
Vaccine Trials
Network.
First, in 2001, CRI formed a partnership with the Ludwig Institute for Cancer
Research to develop the Cancer
Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production faci
Vaccine Collaborative (CVC)-- a centralized, academic, global
network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer
vaccine production faci
vaccine production facilities.